Programmed cell death protein 1 activation preferentially inhibits CD28.CAR–T cells
- 1 October 2018
- journal article
- research article
- Published by Elsevier BV in Cytotherapy
- Vol. 20 (10), 1259-1266
- https://doi.org/10.1016/j.jcyt.2018.07.005
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid TumorsCancer Research, 2016
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptorsNature Medicine, 2015
- Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-TCancer Immunology, Immunotherapy, 2015
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 2014
- Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid TumorsClinical Cancer Research, 2014
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T CellsClinical Cancer Research, 2013
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infectionNature Immunology, 2008
- New Immunotoxins Targeting CD123, a Stem Cell Antigen on Acute Myeloid Leukemia CellsJournal of Immunotherapy, 2007
- T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cellsBlood, 2006
- Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemiaLeukemia, 2004